Core Viewpoint - ST Unimed (002581.SZ) announced that its wholly-owned subsidiary, Shandong Yandu Biotechnology Co., Ltd., has received ethical approval from the Ethics Committee of Beijing Tongren Hospital, affiliated with Capital Medical University, to conduct a Phase III clinical trial for its innovative drug, recombinant human nerve growth factor SMR001 eye drops, aimed at treating moderate to severe dry eye syndrome [1] Summary by Categories Company Developments - The ethical approval for the Phase III clinical trial signifies that the project has met the necessary ethical compliance requirements to proceed [1] - The initiation of this clinical trial is not expected to have a significant impact on the company's operating performance in the short term [1]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 湯臣集團有限公司（於開曼群島註冊成立之有限公司） 呈交日期: 2025年11月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00258 | 說明 不適用 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 3,000,000,000 | HKD | | 0.5 HKD | | 1,500,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 3,000,000,000 | HKD | | 0.5 HKD | | 1,500,000, ...

Core Points - ST Unimed (002581.SZ) released its Q3 2025 financial report on October 29, 2025 [1] - As of October 28, 2025, six institutional investors disclosed holdings in ST Unimed A-shares, totaling 139 million shares, which represents 21.07% of the total share capital [1] - The institutional investors include Xiamen Hengxing Group Co., Ltd., Shenzhen Jialian Private Securities Investment Fund Management Co., Ltd. - Jialian No. 1 Securities Investment Fund, Shenzhen Yilian Technology Co., Ltd., Shenzhen Juyunlai Investment Partnership (Limited Partnership), Beijing Peking University Unimed Bioengineering Group Co., Ltd., and Shenwan Hongyuan Securities Co., Ltd. [1] - The total institutional holding percentage decreased by 1.31 percentage points compared to the previous quarter [1] - In terms of public funds, 13 public funds were not disclosed in this period compared to the previous quarter, including Southern CSI 1000 ETF, Huaxia CSI 1000 ETF, GF CSI 1000 ETF, Fortune CSI 1000 Index Enhanced A, and China Merchants CSI 1000 Index Enhanced A [1]

Core Viewpoint - Company *ST Weihai (002586.SZ) has been identified as the preferred bidder for the "Huaihe River to Sea Waterway Phase II Project (within Huai'an City) River Engineering Construction Package 14" with a bid price of 313 million yuan [1] Summary by Category - **Project Details** - The project involves river engineering construction as part of the Huaihe River to Sea Waterway Phase II [1] - The public announcement period for the bid is from October 11, 2025, to October 14, 2025 [1]

Core Points - Company *ST Weihai has been identified as the preferred bidder for the "Huaihe River Estuary Phase II Project (within Huai'an City) River Engineering Construction Lot 14" [1] - The bid amount for the project is 312,956,420.04 yuan, with the final contract amount to be determined upon signing [1] - The public announcement period for this bid is from October 11, 2025, to October 14, 2025 [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 FF301 致：香港交易及結算所有限公司 公司名稱: 湯臣集團有限公司（於開曼群島註冊成立之有限公司） 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00258 | 說明 | 不適用 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 3,000,000,000 | HKD | | 0.5 HKD | | 1,500,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | 0 | | 本月底結存 | | | 3,000,000,000 | HKD | | 0.5 HKD | | 1,500,000,0 ...

TOMSON GROUP LIMITED 湯 臣 集 團 有 限 公 司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） （Stock Code 股份代號：258） If you for any reason have difficulty in receiving email notification or gaining access to the Websites and would like to receive the Interim Report and all future Corporate Communications2 in printed form, please complete and sign the Request Form on the reverse side of this notification letter and return it to the Company's share registrar in Hong Kong (the "Share Registr ...

TOMSON GROUP LIMITED 湯 臣 集 團 有 限 公 司 (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立之有限公司） （Stock Code 股份代號：258） NOTIFICATION LETTER 通知信函 Dear Registered Shareholder(s), If you for any reason have difficulty in receiving email notification or gaining access to the Websites and would like to receive the Interim Report and all future Corporate Communications in printed form, please complete and sign the Reply Form on the reverse side of this notification letter and return it to the Comp ...

INTERIM REPORT 2025 中期報告 CONTENTS 目錄 | | Page | | 頁次 | | --- | --- | --- | --- | | Corporate Information | 1 | 公司資料 | 2 | | Interim Results | 3 | 中期業績 | 4 | | Interests and Short Positions in Securities | 21 | 證券之權益及淡倉 | 22 | | Corporate Governance and Other | 29 | 企業管治及其他資料 | 30 | | Information | | | | | Condensed Consolidated Statement of | 33 | 簡明綜合損益表 | 33 | | Profit or Loss | | | | | Condensed Consolidated Statement of | 34 | 簡明綜合損益及其他 | 34 | | Profit or Loss and | | 全面收益表 | | | Other Comprehensive Inc ...

Trading Information Summary - As of September 11, 2025, ST Unimed (002581) closed at 7.73 yuan, down 1.28%, with a trading volume of 641.1 million yuan and a year-to-date decline of 29.88% [1][3] - In the last 10 trading days, the main funds have seen a net inflow of 18.21 million yuan, with the stock price increasing by 5.66% during the same period [1][3] Fund Flow Analysis - On September 11, 2025, the main funds experienced a net outflow of 856,300 yuan, while retail funds saw a net inflow of 500,700 yuan [1] Company Announcement Summary - The board of directors of Shandong Unimed Biopharmaceutical Co., Ltd. confirmed the legality and validity of the 2025 stock option incentive plan's candidate list, which was publicly announced internally from August 29 to September 10, 2025, with no objections received [1][3]